High-Level Overview
Shift Labs is a Seattle-based medical device company specializing in simple, affordable infusion therapy solutions, primarily through its flagship product, the DripAssist Infusion Rate Monitoring Platform. This FDA-cleared device enables safe, accurate, and remote monitoring of gravity IV infusions, serving diverse healthcare settings including home care, hospitals, veterinary care, and emerging markets. By providing precise infusion monitoring at a fraction of the cost of traditional infusion pumps, Shift Labs addresses critical patient safety and operational efficiency challenges in infusion therapy. The company has demonstrated strong growth momentum, notably doubling revenue during the COVID-19 pandemic due to increased reliance on gravity infusion and expanding its connected device offerings across multiple markets[1][4][5].
Origin Story
Founded in 2012 by Beth Kolko, a University of Washington professor and experienced entrepreneur, Shift Labs emerged from a vision to create well-designed, affordable medical devices that balance technology and design. The idea was driven by the need for accessible healthcare solutions that serve fast-growing markets, from home health care in the US to clinical care in emerging economies. Early recognition came with the DripAssist device being named one of Popular Science Magazine’s 12 Best Healthcare Innovations of 2016 and receiving multiple awards and grants, including funding from USAID and the US Air Force. These milestones validated the product’s impact and helped the company gain traction in both developed and emerging healthcare sectors[1][4].
Core Differentiators
- Product Differentiators: DripAssist offers precise, automatic monitoring of gravity IV infusions, a low-cost alternative to expensive infusion pumps, enabling safer and more efficient fluid delivery.
- Developer Experience: The device integrates technology and industrial design to create a user-friendly, reliable platform suitable for diverse care environments.
- Speed, Pricing, Ease of Use: The platform reduces operational costs and simplifies workflows, making infusion monitoring accessible in resource-limited settings.
- Community Ecosystem: Shift Labs supports a broad healthcare ecosystem, including home care, hospitals, veterinary, and public health sectors, with a focus on emerging markets and alternative care sites.
- Recognition and Support: The company has received prestigious awards and government grants, highlighting its innovation and impact in global health[1][4][5].
Role in the Broader Tech Landscape
Shift Labs rides the growing trend of decentralizing healthcare delivery and increasing demand for affordable, connected medical devices that enable remote patient monitoring. The timing is critical as healthcare systems worldwide face pressures to reduce costs while improving patient safety, especially in the wake of the COVID-19 pandemic which accelerated reliance on gravity IV infusions. Market forces such as aging populations, rising chronic disease prevalence, and expansion of home and outpatient care settings favor Shift Labs’ solutions. By providing actionable data insights and enabling value-based care, Shift Labs influences the broader ecosystem by bridging technology, design, and global health needs, particularly in underserved regions[1][5].
Quick Take & Future Outlook
Shift Labs is poised for continued growth as it expands its connected device platform across acute and non-acute care markets. Future trends shaping its journey include increased adoption of remote monitoring technologies, integration with digital health platforms, and growing emphasis on cost-effective care delivery in emerging markets. As healthcare moves toward more data-driven, patient-centered models, Shift Labs’ emphasis on simplicity, affordability, and design positions it to deepen its influence in infusion therapy and beyond. The company’s commitment to doing well financially while doing good socially suggests a sustainable path forward, reinforcing its founding mission that *Simple Saves Lives*[4][5].
